- Article
Enhancing the Total Terminal Galactosylation of CHO Cell-Derived TNF-α Blocker-IgG1 Monoclonal Antibody Using Time-Dependent Galactose Supplementation
- Mallikarjuna Pulipeta,
- Pradeep Kumar Iyer,
- Rajendra Kumar Palakurthy,
- Narasimha Pullaguri,
- Rajasekhar Pinnamaneni and
- Srinivas Reddy Chilukuri
Background: Recombinant monoclonal antibodies represent a vital category of biologics, constituting the largest class of molecules used to treat autoimmune disorders, cancers, rheumatoid arthritis, and other chronic conditions. The IgG1 subclass is t...

